A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination With Nivolumab as a Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma
Latest Information Update: 26 Feb 2024
At a glance
- Drugs GT 90001 (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Suzhou Kintor Pharmaceuticals
- 20 Feb 2024 Planned End Date changed from 31 Dec 2024 to 1 Dec 2025.
- 20 Feb 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2025.
- 20 Feb 2024 Status changed from recruiting to active, no longer recruiting.